MX360047B - Unidad sólida con alto contenido en fexofenadina y su procedimiento de preparación. - Google Patents

Unidad sólida con alto contenido en fexofenadina y su procedimiento de preparación.

Info

Publication number
MX360047B
MX360047B MX2015008068A MX2015008068A MX360047B MX 360047 B MX360047 B MX 360047B MX 2015008068 A MX2015008068 A MX 2015008068A MX 2015008068 A MX2015008068 A MX 2015008068A MX 360047 B MX360047 B MX 360047B
Authority
MX
Mexico
Prior art keywords
preparation
solid unit
fexofenadine
content
fexofenadine content
Prior art date
Application number
MX2015008068A
Other languages
English (en)
Other versions
MX2015008068A (es
Inventor
Merillon Baptiste
Lanne Jean-Yves
Renouard Marie
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47902228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX360047(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2015008068A publication Critical patent/MX2015008068A/es
Publication of MX360047B publication Critical patent/MX360047B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas, destinadas a ser utilizadas en forma de unidad sólida tal como un comprimido, para una administración por vía oral, que comprenden un alto contenido en fexofenadina y/o en al menos una de sus sales farmacéuticamente aceptables, así como a los procedimientos de fabricación de unidades sólidas por vía hot melt.
MX2015008068A 2012-12-21 2013-12-20 Unidad sólida con alto contenido en fexofenadina y su procedimiento de preparación. MX360047B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1262647A FR2999937B1 (fr) 2012-12-21 2012-12-21 Unite solide a haute teneur en fexofenadine et son procede de preparation
PCT/EP2013/077752 WO2014096387A1 (en) 2012-12-21 2013-12-20 Solid unit with high fexofenadine content and process for the preparation thereof

Publications (2)

Publication Number Publication Date
MX2015008068A MX2015008068A (es) 2016-04-25
MX360047B true MX360047B (es) 2018-10-19

Family

ID=47902228

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008068A MX360047B (es) 2012-12-21 2013-12-20 Unidad sólida con alto contenido en fexofenadina y su procedimiento de preparación.

Country Status (25)

Country Link
US (1) US9757340B2 (es)
EP (1) EP2934491B1 (es)
JP (1) JP6276287B2 (es)
KR (1) KR20150100725A (es)
CN (1) CN105073101B (es)
AR (1) AR094146A1 (es)
AU (1) AU2013366512B2 (es)
BR (1) BR112015014137B8 (es)
CA (1) CA2895607A1 (es)
CL (1) CL2015001681A1 (es)
EA (1) EA030982B1 (es)
ES (1) ES2625447T3 (es)
FR (1) FR2999937B1 (es)
HK (1) HK1211234A1 (es)
HU (1) HUE032393T2 (es)
IL (1) IL239267A0 (es)
MX (1) MX360047B (es)
PH (1) PH12015501377A1 (es)
PL (1) PL2934491T3 (es)
SG (1) SG11201504394TA (es)
TN (1) TN2015000267A1 (es)
TW (1) TWI624275B (es)
UY (1) UY35235A (es)
WO (1) WO2014096387A1 (es)
ZA (1) ZA201504079B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015138710A (ru) 2013-02-14 2017-03-20 Санофи Жевательная композиция для перорального приема и способ ее получения
WO2017073738A1 (ja) * 2015-10-29 2017-05-04 日本臓器製薬株式会社 フェキソフェナジンを有効成分とする錠剤
KR20220123689A (ko) 2020-03-11 2022-09-08 사와이세이야쿠 가부시키가이샤 과립 및 그것을 이용한 제제
WO2023145871A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法
WO2023145869A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK164642C (da) * 1984-08-30 1992-12-14 Merrell Dow Pharma Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
CN1044319C (zh) * 1984-08-30 1999-07-28 默里尔多药物公司 热熔融抗组胺组合物的制备方法
KR100405116B1 (ko) 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. 피페리디노알칸올화합물에대한약제학적조성물
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
EP1454635B1 (en) * 2003-03-07 2007-12-19 Ind-Swift Limited Tasteless, directly compressible, fast-dissolving complexes and pharmaceutical formulations thereof
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
RU2015138710A (ru) 2013-02-14 2017-03-20 Санофи Жевательная композиция для перорального приема и способ ее получения

Also Published As

Publication number Publication date
UY35235A (es) 2014-07-31
CL2015001681A1 (es) 2015-08-21
FR2999937B1 (fr) 2015-01-09
BR112015014137B8 (pt) 2023-01-24
TN2015000267A1 (en) 2016-10-03
BR112015014137B1 (pt) 2022-12-13
JP2016511223A (ja) 2016-04-14
PH12015501377A1 (en) 2015-09-02
JP6276287B2 (ja) 2018-02-07
FR2999937A1 (fr) 2014-06-27
EP2934491A1 (en) 2015-10-28
AR094146A1 (es) 2015-07-15
TWI624275B (zh) 2018-05-21
KR20150100725A (ko) 2015-09-02
SG11201504394TA (en) 2015-07-30
PL2934491T3 (pl) 2017-09-29
ZA201504079B (en) 2016-04-28
CA2895607A1 (en) 2014-06-26
MX2015008068A (es) 2016-04-25
US9757340B2 (en) 2017-09-12
TW201431569A (zh) 2014-08-16
EP2934491B1 (en) 2017-02-22
ES2625447T3 (es) 2017-07-19
HK1211234A1 (en) 2016-05-20
CN105073101B (zh) 2018-10-09
CN105073101A (zh) 2015-11-18
WO2014096387A1 (en) 2014-06-26
AU2013366512B2 (en) 2017-11-09
HUE032393T2 (en) 2017-09-28
AU2013366512A1 (en) 2015-07-09
EA201591150A1 (ru) 2015-11-30
US20150313885A1 (en) 2015-11-05
EA030982B1 (ru) 2018-10-31
IL239267A0 (en) 2015-07-30
BR112015014137A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
GB201106743D0 (en) Novel compounds
MX369121B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MX2013001677A (es) Formulaciones estables de linaclotida.
WO2011104652A3 (en) Veterinary compositions
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2016003754A (es) Una composicion farmaceutica estable que contiene amlodipina y valsartan.
IL227024A (en) The 3 heteroarylamino propionic acid derivatives are converted into amino acids, a process for their preparation, their use in the preparation of medicinal preparations and as medical preparations containing them
PH12014502856A1 (en) Solid pharmaceutical preparation containing levothyroxine
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
MD4615B1 (ro) Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
WO2014006635A3 (en) Solid oral compositions of silodosin
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
MX370184B (es) Composición farmacéutica que comprende fingolimod.
WO2015022560A8 (en) Stable pharmaceutical composition containing bisoprolol and ramipril
WO2014122671A3 (en) Solid oral compositions of saxagliptin
IN2013CH04314A (es)
MX2015011099A (es) Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.
IN2013MU02059A (es)
WO2014141298A3 (en) Stable pharmaceutical composition of fingolimod

Legal Events

Date Code Title Description
FG Grant or registration